Inhaled Salmeterol/Fluticasone Propionate Combination

Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee.

1998 • 1,813 citations

Determining a minimal important change in a disease-specific quality of life questionnaire

1994 • 1,808 citations

A 15-Year Follow-up Study of Ventilatory Function in Adults with Asthma

1998 • 1,266 citations

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.

1992 • 1,219 citations

Low-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma

2000 • 1,085 citations

Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study

2000 • 1,058 citations

Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS)

1996 • 996 citations

Measuring Quality of Life in Asthma

1993 • 902 citations

Noncompliance and treatment failure in children with asthma☆☆☆★

1996 • 645 citations

The costs of asthma

1996 • 451 citations

Scientific rationale for inhaled combination therapy with long-acting β₂-agonists and corticosteroids

2002 • 447 citations

Changing prevalence of allergic rhinitis and asthma

1999 • 394 citations

Ligand-independent Activation of the Glucocorticoid Receptor by β2-Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and Vascular Smooth Muscle Cells

1999 • 382 citations

Underdiagnosis and Undertreatment of Asthma in the Elderly

1999 • 334 citations

Costs of asthma are correlated with severity: a 1-yr prospective study

2001 • 327 citations

Comparing The National Economic Burden Of Five Chronic Conditions

2001 • 326 citations

The Burden of Asthma in the United States

2002 • 297 citations

Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo.

1995 • 250 citations

Compliance in asthma

1999 • 250 citations

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial

2000 • 249 citations

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

2000 • 238 citations

Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECRHS)

1997 • 211 citations

Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma

2000 • 208 citations

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers

2003 • 199 citations

Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone

2001 • 199 citations

Prevalence of asthma in adults in Busselton, Western Australia.

1992 • 195 citations

Salmeterol/fluticasone propionate (50500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma

1999 • 165 citations

The natural history of asthma in adults: The problem of irreversibility

1999 • 155 citations

Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population.

2001 • 142 citations

Persistent asthma: disease control, resource utilisation and direct costs

2002 • 135 citations

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa.

1997 • 131 citations

Epidemiology of asthma: the year in review

2000 • 127 citations

Patient weighting of importance of asthma symptoms

2001 • 123 citations

Achieving guideline-based asthma control: does the patient benefit?

2002 • 123 citations

Chapters 1-3

2003 • 120 citations

Improving patient compliance with asthma therapy

2000 • 118 citations

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma

2003 • 115 citations

Mortality in adults with self-reported asthma

1996 • 115 citations

Salmeterol/fluticasone propionate (50/100 ?g) in combination in a Diskus? inhaler (Seretide?) is effective and safe in children with asthma

2000 • 112 citations

Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease.

1995 • 110 citations

Respiratory medications and risk of asthma death

2002 • 108 citations

Salmeterol and Fluticasone Propionate (50/250 μg) Administered via Combination Diskus Inhaler: As Effective as When Given via Separate Diskus Inhalers

1999 • 103 citations

Development of an Economic Model to Assess the Cost Effectiveness of Asthma Management Strategies

2002 • 101 citations

Categorizing Asthma Severity

1999 • 97 citations

Salmeterol/fluticasone propionate combination therapy 50/250 μ g twice daily is more effective than budesonide 800 μ g twice daily in treating moderate to severe asthma

2000 • 89 citations

Prospective study of the patient‐level cost of asthma care in children*

2001 • 88 citations

Compliance with US asthma management guidelines and specialty care: a regional variation or national concern?

1999 • 86 citations

Direct and indirect costs of asthma to an employer

2002 • 85 citations

Advair: Combination treatment with fluticasone propionate/salmeterol in the treatment of asthma

2001 • 84 citations

Salmeterol/Fluticasone Combination Inhaler

1998 • 81 citations

Health Care Utilization and Cost in Children with Asthma and Selected Comorbidities

2001 • 76 citations

PATIENT PERCEPTION OF THE DISKUS INHALER: A COMPARISON WITH THE TURBUHALER INHALER

1996 • 74 citations

Noncompliance with Asthma Therapy—Are There Solutions?

2000 • 74 citations

Inhaled corticosteroids plus salmeterol or montelukast: Effects on resource utilization and costs

2002 • 72 citations

Comparison of Fluticasone Propionate–Salmeterol Combination Therapy and Montelukast in Patients Who Are Symptomatic on Short-acting β₂-Agonists Alone

2001 • 68 citations

Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms.

1997 • 59 citations

Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma

2002 • 57 citations

Patient factors and compliance with asthma therapy

1999 • 56 citations

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma

2002 • 56 citations

Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of SeretideTM (50/250 μg bd DiskusTM vs. formoterol (12 μg bd) and budesonide (800 μg bd) given concurrently (both via TurbuhalerTM) in patients with moderate-to-severe asthma

2002 • 55 citations

Impact of a multidisciplinary day program on disease and healthcare costs in children and adolescents with severe asthma: A two‐year follow‐up study

2001 • 54 citations

Asthma: from childhood to adulthood

1996 • 51 citations

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μ g twice daily and budesonide 800 μ g twice daily in the treatment of adults and adolescents with asthma

2000 • 49 citations

Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a–beclomethasone alone

2002 • 47 citations

Interactions between Corticosteroids and β -Adrenergic Agonists in Asthma Disease Induction, Progression, and Exacerbation

2000 • 46 citations

Inhaled Salmeterol/Fluticasone Propionate Combination

2000 • 45 citations

Two-Year Retrospective Economic Evaluation of Three Dual-Controller Therapies Used in the Treatment of Asthma

2002 • 44 citations

Cost-Effectiveness Comparison of Salmeterol/Fluticasone Propionate versus Montelukast in the Treatment of Adults with Persistent Asthma

2002 • 43 citations

Cost-Effectiveness of Adding an Electron-Beam Boost to Tangential Radiation Therapy in Patients With Negative Margins After Conservative Surgery for Early-Stage Breast Cancer

2000 • 41 citations

Impact of Inhaled Salmeterol/Fluticasone Propionate Combination Product versus Budesonide on the Health-Related Quality of Life of Patients with Asthma

2002 • 38 citations

Comparison of Salmeterol/Fluticasone Propionate Combination with Budesonide in Patients with Mild-to-Moderate Asthma

2001 • 38 citations

Cost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/100??g vs Fluticasone Propionate 100??g in Adults and Adolescents with Asthma III: Results

1999 • 38 citations

Epidemiologie und Kosten von Asthma bronchiale und chronischer Bronchitis in Deutschland

2001 • 31 citations

Forecasted State-Specific Estimates of Self-Reported Asthma Prevalence-- United States, 1998

1999 • 30 citations

Effect of salmeterol on patients' adherence to their prescribed refills for inhaled corticosteroids

2000 • 29 citations

Using Humanistic Health Outcomes Data in Asthma

2001 • 26 citations

Cost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/500??g vs Fluticasone Propionate 500??g in Patients with Corticosteroid-Dependent Asthma V: Results

1999 • 26 citations

A Study on the Clinical Equivalence and Patient Preference of Fluticasone Propionate 250 μg Twice Daily via the Diskus^TM/Accuhaler^TMInhaler or the Diskhaler^TM* Inhaler in Adult Asthmatic Patients

1998 • 24 citations

Combination Therapy with Inhaled Long‐Acting β₂‐Agonists and Inhaled Corticosteroids: A Paradigm Shift in Asthma Management

2002 • 23 citations

Inhaled Salmeterol/Fluticasone Propionate Combination

2000 • 21 citations

Reasons for and costs of hospitalization for pediatric asthma: A prospective 1-year follow-up in a population-based setting

2001 • 18 citations

Cost-Effectiveness Analyses of Salmeterol/Fluticasone Propionate Combination Product and Fluticasone Propionate in Patients with Asthma I: Introduction and Overview

1999 • 17 citations

Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments.

2001 • 12 citations

Using Economic Evaluations to Reduce the Burden of Asthma and Chronic Obstructive Pulmonary Disease

2001 • 11 citations

The Cost Implications of an Asthma Attack

1998 • 9 citations

Using Health Outcomes Data to Inform Decision-Making

2001 • 8 citations

Analysis of Asthma-Related Costs and Patterns of Resource Utilization in a Managed-Care Population

2001 • 7 citations

Fluticasone propionate/salmeterol diskus combination product improves asthma-related quality of life compared with individual components in asthma patients symptomatic on β2 agonists alone

2002 • 6 citations

Quality-of-life in allergic diseases

1998 • 5 citations

Fluticasone propionate/salmeterol Diskus® combination product provides superior asthma control compared with fluticasone propionate and salmeterol alone in patients previously receiving PRN short-acting beta2-agonists alone

2002 • 4 citations

Cost-effectiveness analysis of fluticasone propionate/salmeterol combination versus montelukast in the treatment of adults with asthma

2002 • 3 citations

Budget impact model for determining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France

2002 • 3 citations

RP2: THE NET COST OF ASTHMA TO A US PUBLIC MEDICAID PROGRAM

2001 • 2 citations

PRS17: EPIDEMIOLOGY AND COSTS OF BRONCHIAL ASTHMA AND CHRONIC BRONCHITIS IN GERMANY

2000 • 1 citations

Deleted Work

1955 • 0 citations

Cited By (0)

Loading...